Advanced Ovarian Cancer: New Insights on Making the Most of Mutations and Biomarkers to Inform Treatment Plans
Premiere Date: Thursday, March 3, 2022This activity offers CE credit for:
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, March 3, 2023
Note: Credit Is No Longer Available
 | Robert L. Coleman, MD (Moderator) Gynecologic Oncologist The Woodands, TX Chief Medical Officer, Sarah Cannon Research Institute (SCRI) Co-Director, GOG-Partners Philadelphia, PA |
 | Kathleen Moore, MD, MS Associate Director, Clinical Research Director TSET Phase I Drug Development Unit Virginia Kerley Cade Chair in Developmental Therapeutics Professor, Gynecologic Oncology Stephenson Cancer Center at the University of Oklahoma HSC Oklahoma City, OK |
 | David M. O'Malley, MD Professor Department of Obstetrics and Gynecology Director, Division of Gynecologic Oncology Co-Director, Gyn Oncology Phase I Program The James and Ohio State University College of Medicine Columbus, OH |
Epithelial ovarian cancer (EOC) is the second most common and most lethal gynecological cancer, with more than 21,570 estimated new cases and 13,900 deaths in the United States in 2020; most patients are diagnosed with advanced-stage disease (over 70%), which contributes to a 5-year survival rate of 29%. This high death-to-incidence rate is likely due to a large gap between recommendations and practice, particularly since only 34% of women with ovarian cancer (OC) receive the recommended genetic counseling and comprehensive germline and somatic testing. This genetic testing not only has the potential to improve patient outcomes, but also has implications for family members who may be at increased risk of inherited mutations. As emerging data build on and grow clinician understanding of biomarker and mutation connections that inform the best approaches to therapy, it is imperative that health care professionals (HCPs) receive education on this recent data and how they help shape and give direction to the treatment plans for patients with OC.
In this CME Outfitters Live and OnDemand activity, expert faculty will discuss the importance of germline and somatic genetic, genomic, and other biomarker testing, and how this testing informs treatment plans utilizing newly approved and emerging agents based on their efficacy with specific mutations and biomarkers.
At the end of this CE activity, participants should be able to:
- Incorporate germline and somatic genetic, genomic, and other biomarker testing that is necessary to inform treatment decision-making in OC.
- Evaluate recent evidence of mutation and biomarker connection to treatment efficacy.
Supported by educational grants from AstraZeneca Pharmaceuticals and Merck Sharp & Dohme Corp.
Medical oncologists, gynecologists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning Formats
Enduring material
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Coleman reports the following financial relationships:
Consultant: Agenus Inc.; Alkermes; AstraZeneca; Clovis; Dicphera Pharmaceuticals; Genelux; Genentech (Roche); Genmab; GSK; ImmunoGen, Inc; Janssen Global Services, LLC; OncoQuest; Onxeo; Onxerna; and Regeneron Pharmaceuticals Inc.
Grants: AstraZeneca; Clovis; Genelux Corporation; Genmab; ImmunoGen, Inc; Janssen Global Services, LLC; Merck; and Genentech(Roche).
Personal fees: Agenus Inc.; Alkermes; AstraZeneca; Clovis; Deciphera Pharmaceuticals; Genelux; Genentech (Roche); Genmab; GSK; ImmunoGen, Inc; Janssen Global Services, LLC; OncoQuest; Onxeo; Onxerna; and Regeneron Pharmaceuticals Inc. (This is outside of the submitted work)
Research Support: Agenus Inc.; Alkermes; AstraZeneca; Clovis; Dicphera Pharmaceuticals; Genelux; Genentech (Roche); Genmab; GSK; ImmunoGen, Inc; Janssen Global Services, LLC; OncoQuest; Onxeo; Onxerna; and Regeneron Pharmaceuticals Inc.
Dr. Moore reports the following financial relationships:
Consultant/Advisory Boards: AstraZeneca; Aravive, nc.; Alkemeres; Blueprint Medicines Corporation; Elevar Therapeutics; Eisai/Serono; GlaxoSmithKline/Tesaro; Genentech/Roche; ImmunoGen, Inc.; I-Mab Biopharma Co., Ltd; Lilly; Mersana Therapeutics; Mereo BioPharma Group; Merck & Co., Inc.; Myriad Genetics, Inc.; Novartis AG; OncXerna Therapeutics, Inc.; Onconova Therapeutics Inc.; Tarveda Therapeutics; VBL Therapeutics
Research Support: GlaxoSmithKline/Tesaro; Lilly; Merck & Co., Inc.; and PTC Therapeutics
Other financial or material support: GOG Partners Associate Director; and NRG Oncology Ovarian Cancer Chair
Dr. O'Malley reports the following financial relationships:
Advisory Board/Consultant: AbbVie Inc.; Agenus Inc.; Ambry; Amgen; Arquer Diagnostics; AstraZeneca; Celsion Corporation; Clovis Oncology; Corcept Therapeutics; Eisai Co., Ltd.; Elevar Therapeutics; Genentech/Roche; GOG Foundation; ImmunoGen, Inc.; InxMed; Iovance Biotherapeutics; Janssen: Pharmaceutical Companies of Johnson & Johnson; Merck & Co., Inc.; Mersana; Novartis; Novocure; Regeneron; Roche Diagnostics MSA; Rubis Pharma; SDP Oncology (BBI); SeaGen; Sorrento Therapeutics, Inc.; Tesaro/GlaxoSmithKline; and Toray
Grants/Research Support: AbbVie Inc.; Agenus Inc.; Ajinomoto Inc.; Amgen; Array Biopharma; AstraZeneca; Bristol Myers Squibb; Cerulean Pharma Inc.; Clovis Oncology; Eisai Co., Ltd.; EMD Serono; Ergomed; Genentech/Roche; GenMab; GOG Foundation; ImmunoGen, Inc.; INC Research, Inc.; inVentiv Health; Iovance Biotherapeutics; Janssen; Pharmaceutical Companies of Johnson & Johnson; Ludwig Cancer Research; Merck & Co., Inc.; Mersana; New Mexico Cancer Care Alliance; Novocure; PRA Intl; Regeneron; SDP Oncology (BBI); SeaGen; Stemcentrx, Inc.; Takeda; Tesaro/GlaxoSmithKline; TRACON Pharmaceuticals, Inc.; VentiRx Pharmaceuticals, Inc.; and Yale University
Other financial or material support: Elvar Therapeutics and Tarveda Therapeutics
The following CME Outfitters staff have no financial relationships to disclose:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
TV-148-030322-90
